Journal of clinical and experimental hematopathology : JCEH最新文献

{"title":"Anaplastic lymphoma kinase-positive large B-cell lymphoma presenting as a submucosal tumor-like lesion at the esophagogastric junction: a diagnostic pitfall.","authors":"Hidetoshi Satomi, Mioka Kishida, Keiichiro Honma","doi":"10.3960/jslrt.26049","DOIUrl":"https://doi.org/10.3960/jslrt.26049","url":null,"abstract":"<p><p>Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma (LBCL) is a rare, aggressive variant of diffuse LBCL with an immunoblastic/plasmablastic morphology, a plasmacytic immunophenotype with loss of conventional B-cell antigens, and granular cytoplasmic ALK expression. Involvement of the gastrointestinal tract has been documented only in the stomach, duodenum, and ileum. To the best of our knowledge, we report the first case presenting at the esophagogastric junction. A 71-year-old immunocompetent man with Parkinson's disease was referred for progressive anemia that had been detected incidentally, and was found to have a submucosal tumor-like lesion with surface ulceration at the esophagogastric junction, despite a normal serum lactate dehydrogenase level. An endoscopic biopsy revealed diffuse sheets of large immunoblastic and plasmablastic cells. The cells were positive for CD138, multiple myeloma oncogene 1 (MUM1), epithelial membrane antigen (EMA), c-Myc, and CD4; exhibited lambda light-chain restriction; displayed granular cytoplasmic ALK positivity; and weakly expressed CD79a and paired box 5 (PAX5) in Golgi pattern and diffuse patterns, respectively. They were negative for CD30, CD3, CD5, CD8, Epstein-Barr virus-encoded small RNA, human herpesvirus-8, and pan-cytokeratin. Break-apart fluorescence in situ hybridization confirmed ALK rearrangement. Positron emission tomography demonstrated Ann Arbor stage IV disease, with nodal region involvement on both sides of the diaphragm in addition to the gastric cardia. This case illustrates a multilayered clinical, morphological, and immunophenotypic diagnostic pitfall, which was nonetheless resolved through endoscopic biopsy alone. The diagnostic value of this report lies in the lessons for avoiding misdiagnosis rather than in the rarity of the anatomical site.</p>","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149168667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term remission of chronic-type adult T-cell leukemia/lymphoma associated with Graves' disease treated with methimazole.","authors":"Shigeo Fuji, Kako Suzuki, Eri Watanabe, Kazumi Tsuchiya, Makoto Yamagishi","doi":"10.3960/jslrt.26028","DOIUrl":"10.3960/jslrt.26028","url":null,"abstract":"<p><p>Adult T-cell leukemia/lymphoma (ATL) is a rare T-cell malignancy, where the chronic type often progresses to an acute form in the presence of poor prognostic factors. We report a remarkable case of chronic-type ATL that achieved long-term hematologic and molecular remission following methimazole treatment for concomitant Graves' disease. A 58-year-old woman was diagnosed with chronic-type ATL in 2022. Her disease showed gradual progression with elevated soluble interleukin-2 receptor (sIL-2R) levels and lactate dehydrogenase. In 2023, she developed Sjögren's syndrome and Graves' disease. Following the initiation of methimazole for hyperthyroidism, her abnormal lymphocyte counts and sIL-2R levels unexpectedly and rapidly decreased. She has maintained clinical stability for over two years without any cytotoxic chemotherapy. Multi-color flow cytometry confirmed the disappearance of the CD4+/CADM1+/CD7- ATL cell population in the peripheral blood. Furthermore, longitudinal genomic profiling using Target-seq revealed a significant reduction in the variant allele frequencies of major driver clones, including a PDCD1 frameshift mutation, and a shift from monoclonal expansion to a polyclonal HTLV-1 carrier state. This case provides the first clinical evidence of a potential anti-ATL effect of methimazole and underscores the importance of the endocrine-immune axis in HTLV-1-associated malignancies, warranting further investigation into antithyroid therapy as a novel treatment strategy for indolent ATL.</p>","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"244-247"},"PeriodicalIF":1.4,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148623682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world comparison of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone and anthracycline-based regimens in peripheral T-cell lymphoma: A multicenter retrospective study from the Gifu Hematology Study Group.","authors":"Nobuhiko Nakamura, Nobuhiro Kanemura, Naoki Hayase, Yuto Kaneda, Yoshikazu Ikoma, Takayuki Goto, Tomomi Suzaki, Junichi Kitagawa, Senji Kasahara, Toshiki Yamada, Michio Sawada, Kenji Fukuno, Eri Takada, Hideko Goto, Shin Lee, Kei Fujita, Tetsuji Morishita, Takeshi Hara, Hisashi Tsurumi, Masahito Shimizu","doi":"10.3960/jslrt.26008","DOIUrl":"10.3960/jslrt.26008","url":null,"abstract":"<p><p>Background Brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV-CHP) has demonstrated survival benefits over cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with CD30-positive peripheral T-cell lymphoma (PTCL) in a randomized, clinical trial. However, data on the real-world effectiveness of BV-CHP in routine clinical practice remain limited.Methods We conducted a multicenter, retrospective cohort study of patients with newly diagnosed PTCL treated at institutions within the Gifu Hematology Study Group. Patients received BV-CHP, CHOP, or cyclophosphamide, pirarubicin, vincristine, and prednisone (THP-COP) as first-line therapy. Progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) were compared among the treatment groups. Exploratory subgroup analyses were performed, including analyses by bone marrow involvement at diagnosis.Results A total of 154 patients were included: 29 received BV-CHP, 72 received CHOP, and 53 received THP-COP. Overall, no significant differences were observed in PFS, OS, or ORR among the three treatment groups. In exploratory subgroup analyses, patients with bone marrow involvement who were treated with BV-CHP (n = 4) had significantly shorter PFS than those treated with CHOP (n = 17) or THP-COP (n = 15), whereas no significant difference in OS was observed.Conclusions In this real-world multicenter cohort from the Gifu Hematology Study Group, frontline BV-CHP did not demonstrate a survival advantage over CHOP or THP-COP in unselected patients with PTCL. These findings suggest that THP-COP remains a reasonable first-line treatment option in routine clinical practice. The inferior PFS observed in patients with bone marrow involvement treated with BV-CHP should be interpreted cautiously and warrants further investigation.</p>","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"199-208"},"PeriodicalIF":1.4,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148623664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Pola-R-CHP and R-CHOP for newly diagnosed DLBCL: A single-center retrospective study.","authors":"Kaori Akita, Atsushi Takahata, Wataru Tokuyama, Naoya Nakamura, Shigeo Toyota","doi":"10.3960/jslrt.26017","DOIUrl":"10.3960/jslrt.26017","url":null,"abstract":"<p><p>Background Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone (Pola-R-CHP) has become a first-line treatment option for diffuse large B-cell lymphoma (DLBCL), but real-world data remain limited. We retrospectively compared Pola-R-CHP and R-CHOP in patients with newly diagnosed DLBCL.</p><p><strong>Methods: </strong>We analyzed 127 patients who received first-line Pola-R-CHP (n = 57) or R-CHOP (n = 70) at a single center between January 2021 and August 2025. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS) and adverse events. A 120-day landmark analysis, subgroup analyses, and exploratory analysis for sepsis were also performed.</p><p><strong>Results: </strong>Median age was 75 years in the Pola-R-CHP group and 79.5 years in the R-CHOP group; patients aged >80 years were more frequent in the R-CHOP group (21.1% vs 47.1%, P = 0.003). 1-year PFS was 83.9% with Pola-R-CHP and 76.9% with R-CHOP (P = 0.56). 1-year OS was 89.8% and 91.1%, respectively (P = 0.61). In the 120-day landmark analysis, no significant difference in PFS was observed (HR 0.68, 95% CI 0.29-1.56, P = 0.36). Infection-related treatment discontinuation was more frequent with Pola-R-CHP (12.3% vs 0%, P = 0.003). Sepsis was also more frequent in the Pola-R-CHP group (14.0% vs 4.3%, P = 0.098).</p><p><strong>Conclusions: </strong>In this single-center retrospective cohort, Pola-R-CHP was not associated with a significant improvement in PFS compared with R-CHOP. Infection-related treatment discontinuation was more frequent in the Pola-R-CHP group. Sepsis was also numerically more frequent, highlighting the importance of careful infection monitoring in clinical practice.</p>","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"209-216"},"PeriodicalIF":1.4,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148623727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allogeneic hematopoietic stem cell transplantation achieves complete response in refractory primary mediastinal large B-cell lymphoma after the failure of chemotherapy, CAR-T therapy, and PD-1 blockade.","authors":"Tatsuya Suwabe, Yuri Furuyama, Ayako Kawakami, Takumu Tsuchida, Masaki Mitobe, Hodaka Yonezawa, Takayuki Katagiri, Kyoko Fuse, Yasuhiko Shibasaki, Takashi Ushiki, Masayoshi Masuko, Wataru Munakata, Hiroaki Miyoshi, Koichi Ohshima, Hirohito Sone, Jun Takizawa","doi":"10.3960/jslrt.26007","DOIUrl":"10.3960/jslrt.26007","url":null,"abstract":"<p><p>Primary mediastinal large B-cell lymphoma (PMBCL) typically responds to chemotherapy, and immunotherapies such as chimeric antigen receptor T-cell (CAR-T) therapy and the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab have shown promise in relapsed or refractory cases. However, the sequential use of multiple immunotherapies for PMBCL remains poorly characterized. Here, we report a case of a 19-year-old female with PMBCL involving the mediastinum and multiple extranodal sites. After a partial response to chemotherapy, she developed a central nervous system relapse that responded to high-dose methotrexate, and the number of regrowing mediastinal lesions was reduced by radiotherapy. Subsequently, new hepatic lesions that were refractory to both CAR-T therapy and pembrolizumab emerged. Following localized liver radiotherapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) was performed, resulting in complete response. Early post-transplant, she developed a hepatitis variant of acute graft-versus-host disease, which may have reflected a graft-versus-lymphoma (GVL) effect. Despite maintaining response, the patient died one year later form a disseminated infection with multitriazole-resistant Aspergillus fumigatus. This case highlights both the potential curative role and the substantial risks of allo-HSCT in PMBCL refractory to multiple immunotherapies. The pre-transplant use of pembrolizumab and localized radiotherapy may influence transplant outcomes and warrants further investigation.</p>","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"225-230"},"PeriodicalIF":1.4,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148623650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological analysis of oral-cavity B-cell neoplasms: Comparison between non-immunosuppressive and immunosuppressive patients.","authors":"Yuuki Ishii, Mebae Ichikawa, Yusuke Kondo, Joaquim Carreras, Masashi Miyaoka, Yukie Yara Kikuchi, Takayuki Aoki, Yoshihide Ota, Naoya Nakamura","doi":"10.3960/jslrt.25015","DOIUrl":"10.3960/jslrt.25015","url":null,"abstract":"<p><p>No comparative analysis of the infrequently occurring B-cell neoplasms (BCNs) in the oral cavity has yet been reported in patients with non-immunosuppressiveness or immunosuppressiveness. To identify any differences in clinicopathological findings between patients with non-immunosuppressiveness and those with immunosuppressiveness, we compared the clinicopathological characteristics of oral-cavity BCNs in these patient groups. The clinical characteristics of 39 patients were analyzed from hospital records, including 24 with non-immunosuppressiveness and 15 with immunosuppressiveness. Histological and immunohistochemical evaluation was performed using formalin-fixed paraffin-embedded tissue sections. Comparisons between the two groups were conducted using cross-tabulations and the chi-squared or Fisher exact test. In patients with non-immunosuppressiveness, diffuse large B-cell lymphoma (DLBCL) was the most common type (14/24, 58%), followed by mucosa-associated lymphoid tissue lymphoma (MALT-L, 4/24, 17%). In patients with immunosuppressiveness, EBV-positive mucocutaneous ulcers (EBV-MCU) were the most common type (9/15, 60%), followed by DLBCL (3/15, 20%) and polymorphic/lymphoplasmacytic infiltration (3/15, 20%). Macroscopic findings showed 21 masses (88%) and 3 ulcers (13%) in patients with non-immunosuppressiveness and 11 ulcers (73%) and 4 masses (27%) in patients with immunosuppressiveness. Immunohistochemistry revealed that BCNs in patients with non-immunosuppressiveness expressed EBER in only 1 case (1/22, 5%), whereas those in patients with immunosuppressiveness expressed EBER in all cases (15/15, 100%). Our macroscopic findings and EBV status allowed us to distinguish BCNs between patients with non-immunosuppressiveness and those with immunosuppressiveness.</p>","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"189-198"},"PeriodicalIF":1.4,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148623675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment of refractory hemophagocytic lymphohistiocytosis complicating Epstein-Barr virus-positive classic Hodgkin lymphoma with rituximab.","authors":"Satoshi Ichikawa, Yutaka Suzuki, Yuya Tanaka, Keita Kanba, Kensuke Fujita, Yoko Okitsu, Masahiro Kobayashi, Fumiyoshi Fujishima, Junichi Kameoka, Tomonori Ishii","doi":"10.3960/jslrt.26032","DOIUrl":"10.3960/jslrt.26032","url":null,"abstract":"<p><p>Hemophagocytic lymphohistiocytosis (HLH) complicating classic Hodgkin lymphoma (HL-HLH) is a rare but frequently life-threatening condition that is strongly associated with Epstein-Barr virus (EBV) infection, particularly in the mixed-cellularity and lymphocyte-depleted subtypes. No consensus has been reached regarding treatment for HL-HLH, and the myelotoxicity induced by etoposide-based HLH-directed therapy precludes its safe addition to intensive lymphoma-directed chemotherapy, particularly in older patients. We here report the case of a male in his early 70s with advanced EBV-positive mixed-cellularity classic Hodgkin lymphoma (CHL) who presented with cervical lymphadenopathy, fever, hepatosplenomegaly, and a markedly elevated soluble interleukin-2 receptor (sIL-2R) level, along with a high peripheral blood EBV DNA load. EBV-encoded small RNA in situ hybridization confirmed EBV positivity in lymphoma cells. His fever was steroid-refractory, and chemotherapy with brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (BV-AVD) was initiated immediately following the diagnosis was confirmed. However, the persistent high fever did not resolve, and progressive cytopenia, marked hyperferritinemia, and further increase in sIL-2R levels were observed. Repeat bone marrow examinations revealed macrophage activation with hemophagocytosis, confirming HLH as a complication. Rituximab was promptly administered, and the fever resolved within 3 days. Furthermore, ferritin, sIL-2R, and lactate dehydrogenase levels substantially declined within 1 week, with peripheral blood EBV DNA becoming undetectable. BV-AVD was continued without major complications and led to a complete response after six cycles. Rituximab may represent a strategically timed and reasonable adjunctive intervention for EBV-driven HL-HLH that is refractory to, or develops following, chemotherapy for CHL.</p>","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"260-271"},"PeriodicalIF":1.4,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148860665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of diffuse large B-cell lymphoma achieving complete remission with epcoritamab after pseudoprogression.","authors":"Ai Takahara, Yu Yagi, Yusuke Kanemasa, Kaho Fujino, Takahito Kuga, Yusuke Masuda, Nozomi Kanai, Kumiko Fujita, Kento Ishimine, Taro Sawabe, Mano Mino, Taichi Tamura, Shohei Nakamura, Toshihiro Okuya, Shota Kusuhara, Shinichiro Matsuda, Tsunekazu Hishima, Tatsu Shimoyama","doi":"10.3960/jslrt.26023","DOIUrl":"10.3960/jslrt.26023","url":null,"abstract":"<p><p>Although the use of bispecific antibodies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is expanding, reports of pseudoprogression following this therapy are scarce. A 58-year-old, male patient with DLBCL achieved a complete response (CR) after fourth-line therapy with lisocabtagene maraleucel. However, 26 months post-infusion, he experienced the development of pelvic lymphadenopathy, which was histologically confirmed as a relapse. Because the disease was refractory to radiotherapy and chemotherapy, epcoritamab was administered as the seventh-line treatment. A fever developing after the second step-up dose (Cycle 1, day 12) was diagnosed as grade 1 cytokine release syndrome and was treated with acetaminophen. Nonetheless, the fever was still present on day 14, when abdominal pain requiring opioid administration also developed. Computed tomography (CT) revealed enlargement of the pelvic lesions and increased ascites. Cytology of the ascites revealed no lymphoma cells and showed a predominantly inflammatory cell composition, while lactate dehydrogenase levels decreased, supporting the diagnosis of pseudoprogression. The treatment was continued and his symptoms gradually improved. After three cycles, positron emission tomography-CT confirmed the complete metabolic response (CMR), which was maintained through nine cycles. The present case highlights the potential for pseudoprogression to occur during epcoritamab therapy, suggesting that continued treatment may lead to durable remission even in patients with early clinical deterioration.</p>","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"238-243"},"PeriodicalIF":1.4,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148860667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of bone marrow-liver-spleen type diffuse large B-cell lymphoma: importance of rapid diagnosis and therapeutic intervention.","authors":"Hitomi Eda, Kaoru Furihata, Fumiya Ogasawara","doi":"10.3960/jslrt.26011","DOIUrl":"10.3960/jslrt.26011","url":null,"abstract":"<p><p>Bone marrow-liver-spleen (BLS)-type diffuse large B-cell lymphoma (DLBCL) is a rare and aggressive variant characterized by primary involvement of the bone marrow, liver, and spleen without lymphadenopathy. We describe the case of a 73-year-old woman who presented with multiorgan failure complicated by disseminated intravascular coagulation and clinical features suggestive of secondary hemophagocytic lymphohistiocytosis. Prompt initiation of intensive chemotherapy (R-CHOP: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone) guided by characteristic clinical findings including bone marrow smear examination, resulted in rapid clinical improvement and prolonged survival.Rather than representing an unusual diagnostic dilemma, this case illustrates a clinically characteristic and educational presentation of BLS-type DLBCL and highlights the importance of timely lymphoma-directed treatment based on readily available hematologic evidence.</p>","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"231-237"},"PeriodicalIF":1.4,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148623521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diffuse large B-cell lymphoma complicated by cytokine release syndrome and immune effector cell-associated neurotoxicity on day 355 of epcoritamab therapy: a case report.","authors":"Yasunobu Sekiguchi, Kosuke Arai, Shizuka Hamano, Masahisa Kudo, Nobuo Maseki, Yoshie Iizaki, Machiko Kawamura, Kazuhiko Kobayashi, Yu Nishimura, Hiroaki Kanda, Daisuke Takei, Tomoya Abe, Makoto Hanai, Sayaka Endo, Toshiaki Nakayama, Yasumasa Shimano, Hirofumi Kobayashi","doi":"10.3960/jslrt.26004","DOIUrl":"10.3960/jslrt.26004","url":null,"abstract":"","PeriodicalId":520662,"journal":{"name":"Journal of clinical and experimental hematopathology : JCEH","volume":" ","pages":"177-181"},"PeriodicalIF":1.4,"publicationDate":"2026-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13472213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147439119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}